Sanofi joins the myeloid checkpoint movement with Biond deal

Sanofi is staking claims in next-generation checkpoints through a new deal with Israeli biotech Biond around myeloid checkpoint target ILT2. 

The deal with Biond Biologics Ltd., which gives the biotech $125 million up front and over $1 billion in milestones plus tiered double-digit royalties, is Sanofi’s second play for next-generation checkpoints this week as it continues its oncology rebuild...